Diarylquinolines
Showing 1 - 8 of 8
Pulmonary TB Trial in South Africa (Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg,
Recruiting
- Pulmonary TB
- Delamanid + Bedaquiline + OPC-167832 10 mg
- +3 more
-
Tembisa, Gauteng, South Africa
- +7 more
Jun 30, 2022
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary Trial in Worldwide (Linezolid 600 mg, Linezolid 1200 mg
Recruiting
- Tuberculosis, Multidrug-Resistant
- +2 more
- Linezolid 600 mg
- +7 more
-
Gaborone, South-East District, Botswana
- +16 more
Dec 13, 2022
Pulmonary Tuberculosis Trial (Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and
Not yet recruiting
- Pulmonary Tuberculosis
- Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
- +3 more
- (no location specified)
Jul 25, 2023
Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary Trial in Belarus, South
Active, not recruiting
- Tuberculosis, Multidrug-Resistant
- +2 more
- Bedaquiline
- +5 more
-
Minsk, Belarus
- +6 more
May 12, 2021
Healthy Trial in Antwerpen (Bedaquiline (Test formulation), Bedaquiline (Reference formulation))
Completed
- Healthy
- Bedaquiline (Test formulation)
- Bedaquiline (Reference formulation)
-
Antwerpen, BelgiumSGS Life Science Services
Jan 21, 2020
Tuberculosis, Multidrug-Resistant Trial in Kiyose, Sakai (TMC207 (bedaquiline), Background Regimen (BR))
Completed
- Tuberculosis, Multidrug-Resistant
- TMC207 (bedaquiline)
- Background Regimen (BR)
-
Kiyose, Japan
- +1 more
Oct 30, 2019
Multi-drug Resistant Tuberculosis Trial in Worldwide (Arm A Double-blind Phase: TMC207, Arm B Double-blind Phase: Placebo,
Withdrawn
- Multi-drug Resistant Tuberculosis
- Arm A Double-blind Phase: TMC207
- +3 more
-
Porto Alegre, Brazil
- +43 more
Nov 30, 2015
